Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Global Market Report 2025

The castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market size has grown strongly in recent years. It will grow from $7.96 billion in 2024 to $8.43 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth during the historic period can be attributed to the rising incidence of prostate cancer, increased use of androgen deprivation therapy (ADT) resulting in resistance, expanded availability of targeted therapy options, advancements in diagnostic imaging capabilities, and growing healthcare investments in oncology infrastructure.

The castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market size is expected to see strong growth in the next few years. It will grow to $10.48 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The projected growth during the forecast period can be attributed to the increasing adoption of precision oncology and biomarker-driven therapies, rising demand for next-generation hormonal treatments and radioligand therapy, an expanding clinical trial pipeline for advanced prostate cancer, a growing pipeline of targeted and immuno-oncology agents, and a heightened demand for personalized medicine strategies. Key trends expected during this period include the development of combination immunotherapy regimens, the incorporation of genomic profiling into clinical decision-making, the use of digital health tools for patient monitoring, innovations in bispecific T-cell engagers, and advancements in tumor microenvironment modulators.

The increasing prevalence of prostate cancer is anticipated to drive the growth of the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market in the coming years. Prostate cancer is a form of cancer that originates in the prostate gland, a small organ in men located beneath the bladder and in front of the rectum. The growing prevalence of prostate cancer is largely attributed to the aging population, as the likelihood of developing the disease rises significantly with age. Castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics are used to treat advanced stages of prostate cancer that no longer respond to standard hormone therapy. These treatments enhance patient outcomes by slowing disease progression, managing symptoms, and improving quality of life. For example, in November 2024, the National Health Service, a government agency in the UK, reported that new prostate cancer cases reached 54,732 in 2022, reflecting an increase of 11,354 cases compared to 2021. Hence, the rising prevalence of prostate cancer is fueling the growth of the CRPC or HRPCA therapeutics market.

Leading companies in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market are concentrating on the development of innovative products and securing regulatory approvals, such as dual-action tablets, to improve treatment effectiveness and patient outcomes. Dual-action tablets are advanced formulations that combine two therapeutic agents in a single dose to concurrently target multiple pathways involved in the treatment of CRPC. For example, in August 2023, Janssen Pharmaceuticals, a pharmaceutical company based in Belgium, received approval from the U.S. Food and Drug Administration (FDA) for Akeega, a new tablet designed for treating adults with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). Akeega is a precision medicine that integrates a PARP inhibitor (niraparib) with a CYP17 inhibitor (abiraterone acetate), specifically aimed at patients with BRCA mutations. When administered with prednisone, it significantly improves radiographic progression-free survival (rPFS) compared to standard hormonal therapies.

In June 2024, AstraZeneca plc, a pharmaceutical company based in the US, acquired Fusion Pharmaceuticals Inc. for an undisclosed sum. Through this acquisition, AstraZeneca seeks to revolutionize cancer treatment and outcomes by shifting from conventional chemotherapy and radiotherapy to more precise next-generation radioconjugate therapies. Fusion Pharmaceuticals Inc., a biotech firm headquartered in Canada, is actively developing FPI-2265, a targeted alpha therapy intended for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

Major players in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market are Pfizer Inc., Johnson And Johnson, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Lantheus Holdings Inc., POINT Biopharma Global Inc., Clovis Oncology Inc., Arvinas Inc., Clarity Pharmaceuticals Ltd, Modra Pharmaceuticals B.V., Oncternal Therapeutics Inc., Zenith Epigenetics Ltd., ESSA Pharma Inc.

North America was the largest region in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Castration-resistant prostate cancer (CRPC), also known as hormone-refractory prostate cancer (HRPCA), therapeutics include drugs and treatments designed for CRPC - an advanced stage of prostate cancer that continues to advance despite reduced testosterone levels, typically following androgen deprivation therapy. These treatments are intended to address resistance mechanisms, enhance patient outcomes, and prolong survival.

The primary therapy types for castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) include hormonal therapy, chemotherapy, immunotherapy, targeted therapy, and radiation therapy. Hormonal therapy involves using hormones or hormone-blocking medications to inhibit or slow the growth of hormone-sensitive cancers. These treatments are delivered through oral, injectable, and intravenous methods and are utilized by various end users, such as hospitals, oncology centers, ambulatory surgical centers, and others.

The castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market research report is one of a series of new reports that provides castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market statistics, including the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics industry's global market size, regional shares, competitors with the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market share, detailed castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market. This castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market consists of sales of enzalutamide, darolutamide, abiraterone, and cabazitaxel. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.